Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
Cullinan Management (CGEM) Stock Price & Analysis
113 Followers
CGEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.64 - $25.72
Previous Close$25.3
Volume4.75M
Average Volume (3M)639.15K
Market Cap
$717.90M
Enterprise Value$627.12M
Total Cash (Recent Filing)$466.43M
Total Debt (Recent Filing)$3.99M
Price to Earnings (P/E)-6.8
Beta0.95
Next Earnings
May 09, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.70
Shares Outstanding43,065,645
10 Day Avg. Volume1,609,396
30 Day Avg. Volume639,155
Standard Deviation0.15
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.09K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$26.60Price Target Upside5.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Cullinan Management News
PremiumCompany Announcements
Cullinan Management’s Strategic Shift and Capital Raise
Bulls Say, Bears Say
Bulls Say
Clinical DataEarly clinical data for Cullinan's CLN-978 demonstrates rapid, deep, and sustained B-cell depletion, indicating its potential as an effective treatment for autoimmune diseases such as SLE, with a large market opportunity and unmet medical need.
Drug AdvantagesCullinan's '978 T cell engager offers significant advantages in the treatment of autoimmune diseases, including a convenient subcutaneous formulation, once-weekly dosing, and a favorable safety profile, potentially improving patient compliance and outcomes.
Market OpportunityThe autoimmune disease market presents a substantial commercial opportunity for Cullinan, with CD3 bispecifics like CLN-978 offering a promising treatment option that could rival CAR-T therapies in efficacy while minimizing toxicity and logistical challenges.
Bears Say
Clinical TrialsCullinan is discontinuing enrollment in the CLN-978 B-NHL study to focus on autoimmune diseases, following mixed results from the study.
Drug DevelopmentCGEM disclosed that they will no longer develop CLN-978 in Non Hodgkin's Lymphoma (NHL), discontinuing the ongoing Phase 1 trial.
Executive MovementCFO Jeff Trigilio will depart the company, although he will assist in the transition as a consultant until a new CFO is found.
---
Ownership Overview
72.02% Insiders
12.03% Mutual Funds
13.82% Other Institutional Investors
2.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $7.64 and its highest was $25.71 in the past 12 months.
What is Cullinan Management’s market cap?
Currently, no data Available
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is May 09, 2024 which is in 11 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Mar 14, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.961 by $0.421.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -$0.98.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 43,065,643 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.961. Following the earnings report the stock price went down -0.412%.
Which hedge fund is a major shareholder of Cullinan Management?
Among the largest hedge funds holding Cullinan Management’s share is Caxton Associates LP. It holds Cullinan Management’s shares valued at N/A.
---
Cullinan Management Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.60 (5.14% Upside)
$26.60 (5.14% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 18.1%
Last 30 Days ▲ 18.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.49%
12-Months-Change
Fundamentals
Return on Equity
-30.98%
Trailing 12-Months
Asset Growth
-13.55%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
---
CGEM Stock 12 Months Forecast
Average Price Target
$26.60
▲(5.14% Upside)
Technical Analysis
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
12/24 ratings generated profit
1 Year Average Return
+12.10%
reiterated a buy rating 13 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.10% per trade.
---